M. Martín Jiménez

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Mariana Chávez‐MacGregor et al. · Annals of Oncology · 2022 · 57 citations · Full text

Endocrine Oncology, Vs Physician Choice, Advanced/metastatic Breast Cancer +11

Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana’s predictive model

Andrés J. Muñoz Martín, Pilar Alfonso, Ana Belén Rúperez Blanco et al. · Clinical & Translational Oncology · 2014 · 50 citations

Thrombosis, Predictive Model, Venous Thrombosis +9

LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial

Peter A. Fasching, Daniil Stroyakovskiy, Denise A. Yardley et al. · Annals of Oncology · 2024 · 42 citations · Full text

Breast Oncology, Oncology, Lba13 Adjuvant Ribociclib +14

Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors

Pedro León, M. Martín Jiménez, Pascual Barona et al. · Medical and Pediatric Oncology · 1998 · 41 citations